WO2002074231A2 - Compositions cosmetiques et dermopharmaceutiques contenant des extraits titres de hierochloe odorata - Google Patents
Compositions cosmetiques et dermopharmaceutiques contenant des extraits titres de hierochloe odorata Download PDFInfo
- Publication number
- WO2002074231A2 WO2002074231A2 PCT/FR2002/000725 FR0200725W WO02074231A2 WO 2002074231 A2 WO2002074231 A2 WO 2002074231A2 FR 0200725 W FR0200725 W FR 0200725W WO 02074231 A2 WO02074231 A2 WO 02074231A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cosmetic
- compositions according
- dermopharmaceutical
- extracts
- macro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the skin and more particularly the stratum corneum, must have an excellent state of hydration.
- Dry skin is linked to pathophysiological phenomena such as aging, diabetes, ichthyosis, hormonal imbalances, abuse of certain drugs (laxatives, diuretics ). Dry skin does not only represent discomfort for the person affected, but by causing the skin to lose its barrier properties of mechanical separation between the internal environment of the body and the outside world, it creates a dangerous situation for the skin. and for the whole organism.
- the skin then loses its elasticity and its integrity, becomes dry, rough, brittle, which promotes the appearance of local infections, causes a feeling of discomfort with tightness of the skin, triggers excessive scaling and the appearance of scabs in the most exposed places such as the corners of the lips.
- the radical forms of oxygen are to a large extent responsible for these more or less localized tissue manifestations.
- the first consists, in deregulation, at the level of cell membranes, of products of the cascade of arachidonic acid such as prostaglandins (PGE 2 in particular), and which causes painful sensation (Kimura & Okuda, 1987, J. Nat Prod. 50: 392-399).
- the second mechanism is the activation of different types of cells that secrete pro-inflammatory molecules, such as human neutrophils, which release prostaglandins (PGE 2 in particular) as well as other mediators of inflammation, large quantities of collagenase, elastase, and hyaluronidase stored in their azurophilic granules (Nender (1996) J. oflnvest. Med. 44: 531-539), locally causing, by simple mechanical consequence, edema and both capillary fragility that venous.
- pro-inflammatory molecules such as human neutrophils, which release prostaglandins (PGE 2 in particular) as well as other mediators of inflammation, large quantities of collagenase, elastase, and hyaluronidase stored in their azurophilic granules (Nender (1996) J. oflnvest. Med. 44: 531-539), locally causing, by simple mechanical consequence, edema and both capillary fragility that venous.
- Hierochloe odorata also known by different names: Bison grass or ⁇ oly grass or Zebrovka or Sweet grass or Vanilla Grass
- the active molecule responsible for the activities claimed in this patent application was Xumbelliferone.
- umbelliferone which can be used in cosmetic and dermopharmaceutical compositions can therefore be obtained by chemical or enzymatic synthesis, by one of the numerous methodologies of biotechnology, by plant extraction or by any other usable means. allowing it to be obtained at reasonable costs in the finished product so that it can be used industrially.
- any plant species can be suitable from the moment when this plant contains rumbelliferone, such as, for example, Hierochloe odorata.
- rumbelliferone such as, for example, Hierochloe odorata.
- maximum purity will always be sought.
- the umbelliferone assays performed by spectrophotometry or HPLC, show varying concentrations of umbelliferone according to the origins and the picking seasons, between 0.01 and 2.0%, most often between 0.1 and 1%.
- extraction solvents which can be chosen from water, propylene glycol, butylene glycol, glycerin, polyethylene glycol, methyl and / or ethyl ethers of diglycols, cyclic polyols, ethoxylated or propoxylated diglycols, alcohols (methanol, ethanol, propanol, butanol), or any mixture of these solvents.
- Normal human fibroblasts are cultured in a conventional manner.
- the products to be tested (Example 2 and aspirin) and their solvent are brought into contact (by adding to the culture medium) of the cells for 24 hours.
- the culture medium (and therefore the product to be tested) is discarded and replaced with buffer alone.
- the cells are then irradiated (50mJ.cmf 2 ) with UV-B.
- the buffer is then replaced by the culture medium containing the products to be tested or their solvent, under the same conditions as before the irradiation, for a period of 24 hours.
- the supernatants are removed and their PGE2 concentration is determined by a conventional method (Kit Cayman).
- the extracts of Hierochloe odorata were tested at the concentrations indicated in the following table, a positive control was carried out using aspirin (cycloxygenase inhibitor) at the concentration of 0.0001%; the negative control being made by testing the solvent of the product tested.
- Example 5 Hydrating effect in vivo This example demonstrates the hydrating skin effect obtained, in vivo, on the legs of 15 adult female volunteers.
- the skin's hydration level is measured by the skin's electrical capacity using a corneometer (Courage and Khazaka, model CM 820), a technique conventionally used in cosmetology.
- Each cream studied (placebo and Hierochloe odorata extract at different concentrations) is then applied until complete penetration, on an independent site, at a rate of 20 ⁇ l per site.
- the fifth site previously identified does not receive any product.
- the temperature and humidity of the room where the test is carried out are kept constant throughout the test.
- rumbelliferone of whatever origin, including that found in extracts of Hierochloe odorata can be used as such or in cosmetic or dermopharmaceutical preparations for all skin care and especially for obtain hydrating, veinotonic, analgesic, anti-proliferation, immunomodulation, anti-inflammatory and anti-edematous effects.
- umbelliferone of whatever origin (chemical, enzymatic synthesis, by one of the numerous methodologies of biotechnology, or by any other usable means allowing its obtaining at reasonable costs in the finished product to be able to be used industrially) can be used as it is in cosmetic or dermopharmaceutical preparations for all skin care and especially to obtain hydrating, veinotonic, analgesic, anti-proliferation, immuno-modulation, anti-inflammatory and anti-edematous effects.
- rumbelliferone of whatever origin (chemical, enzymatic synthesis, by one of the numerous methodologies of biotechnology, by plant extraction or by any other usable means allowing its obtaining at reasonable costs in the finished product to be able to be used industrially), with other active ingredients in order to reinforce its effect by additivity or synergy between the effects of these different products, or in order to combine the effect described in this application patent with another beneficial physiological effect on the skin, mucous membranes, dander (nails, hair and hair).
- umbelliferone is obtained from any family or species from the moment that it contains umbelliferone, such as, for example, Hierochloe odorata.
- the concentration of umbelliferone in the extract can vary between 0.01 and 100%, most often between 0.1 and 10% (w / w).
- the concentration of umbelliferone can vary between 0.01% and 50% (w / w), preferably between 0.1% and 10% (w / w).
- Umbelliferone of any origin whatsoever, alone or in combination with other active ingredients, is used in any galenic form used in cosmetics or dermopharmacy: O / W and W / O emulsions, milks, lotions, ointments, hair lotions , shampoos, soaps, sticks and pencils, sprays, body oils, without this list being exhaustive.
- Umbelliferone of whatever origin, is used in the form of a solution, dispersion, emulsion, or encapsulated in vectors such as macro-, micro- or nanocapsules, liposomes or chylomicrons, or included in macro-, micro- or nanoparticles, or in micro-sponges, or adsorbed on powdery organic polymers, talcs, bentonites and other mineral supports.
- Umbelliferone whatever its origin, alone or in combination with other active ingredients, is incorporated into any other ingredient usually used: extraction and / or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifiers, principles hydro- or fat-soluble active ingredients, in particular caffeine, plant extracts, tissue extracts, marine extracts, sun filters, antioxidants.
- Umbelliferone of whatever origin, alone or in combination with other active ingredients, is used in cosmetic or dermopharmaceutical compositions; used for all skin care, for moisturizing purposes, veinotonic, analgesic, anti-proliferation, immuno-modulation, anti-inflammatory and anti-edematous.
- Umbelliferone of any origin whatsoever, alone or in combination with other active ingredients, is incorporated into cosmetic or dermopharmaceutical compositions for the preparation of a medicament used for all skin care, particularly for moisturizing purposes, veinotonic, analgesic, anti-proliferation, immuno-modulation, anti-inflammatory and anti-edematous.
- Umbelliferone of any origin whatsoever, alone or in combination with other active ingredients, is incorporated into cosmetic or dermopharmaceutical compositions, linked or incorporated or absorbed or adsorbed in the form of macro-, micro- and nanoparticles or in macro-, micro- and nanocapsules, in textiles, synthetic or natural fibers, wool and any material capable of being used to make clothes and underwear for day or night, directly in contact with the skin or hair to allow continuous topical delivery.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002241071A AU2002241071A1 (en) | 2001-03-20 | 2002-02-28 | Cosmetic and dermopharmaceutical compositions comprising standardised extracts of hierochloe odorata |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0103790A FR2822379B1 (fr) | 2001-03-20 | 2001-03-20 | Compositions cosmetiques et dermopharmaceutiques contenant de l'umbelliferone |
FR01/03790 | 2001-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002074231A2 true WO2002074231A2 (fr) | 2002-09-26 |
WO2002074231A3 WO2002074231A3 (fr) | 2003-02-13 |
Family
ID=8861363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/000725 WO2002074231A2 (fr) | 2001-03-20 | 2002-02-28 | Compositions cosmetiques et dermopharmaceutiques contenant des extraits titres de hierochloe odorata |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002241071A1 (fr) |
FR (1) | FR2822379B1 (fr) |
WO (1) | WO2002074231A2 (fr) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2260173A (en) * | 1938-07-11 | 1941-10-21 | Sherka Chemical Co Inc | Production and application of media for protection from light |
US2590485A (en) * | 1939-06-02 | 1952-03-25 | Lever Brothers Ltd | Process of treating yellowish or off-white materials to obtain a white appearance using umbelliferone or methyl umbelliferone |
DE2632810A1 (de) * | 1976-07-21 | 1978-01-26 | Henkel Kgaa | Haarfaerbemittel |
WO1985003864A1 (fr) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Traitement des oedemes a forte teneur en proteines par application directe de benzo-pyrones |
WO1985003865A1 (fr) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Traitement des oedemes a forte teneur en proteines chez les animaux |
DE3938902C1 (fr) * | 1989-11-24 | 1991-05-08 | Schaper & Bruemmer Gmbh & Co, 3320 Salzgitter, De | |
FR2668932A1 (fr) * | 1990-11-14 | 1992-05-15 | Joseph Henri | Preparation d'un gel contenant un extrait de justicia pectoralis jacq. (acanthacees) indique dans le traitement des pathologies lympho-veineuses. |
WO1993016064A1 (fr) * | 1992-02-13 | 1993-08-19 | BIOSIGNAL, Kutató-Fejleszto^' Kft. | Derives de coumarine et leurs analogues inhibant la proliferation cellulaire et la croissance tumorale, compositions pharmaceutiques les contenant, et leur procede de preparation |
EP0665002A1 (fr) * | 1993-12-30 | 1995-08-02 | L'oreal | Composition protectrice, nutritive et/ou raffermissante pour le traitement simultané des couches superficielles et profonde de la peau, son utilisation |
WO1996029050A1 (fr) * | 1995-03-23 | 1996-09-26 | Pierre Fabre Dermo-Cosmetique | Composition dermatologique et/ou cosmetique depigmentante |
WO1998048768A1 (fr) * | 1997-05-01 | 1998-11-05 | Medlogic Global Corporation | Compositions utilisables en cosmetologie |
WO1999047118A1 (fr) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions pour modifier l'aspect exterieur de la peau |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS231474B1 (cs) * | 1983-03-08 | 1984-11-19 | Jiri Kolinek | Způsob úpravy vodného extraktu z heřmánku pravého /Matricaria chamomilla L./ |
SU1759870A1 (ru) * | 1990-07-02 | 1992-09-07 | Научно-Производственное Питомниководческое Объединение "Сад-Элита" | "Бальзам "Богатырь Иван Поддубный" |
RU2018523C1 (ru) * | 1992-10-23 | 1994-08-30 | Арендное предприятие фирма "Вагрон" | Композиция ингредиентов для настойки |
-
2001
- 2001-03-20 FR FR0103790A patent/FR2822379B1/fr not_active Expired - Lifetime
-
2002
- 2002-02-28 AU AU2002241071A patent/AU2002241071A1/en not_active Abandoned
- 2002-02-28 WO PCT/FR2002/000725 patent/WO2002074231A2/fr not_active Application Discontinuation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2260173A (en) * | 1938-07-11 | 1941-10-21 | Sherka Chemical Co Inc | Production and application of media for protection from light |
US2590485A (en) * | 1939-06-02 | 1952-03-25 | Lever Brothers Ltd | Process of treating yellowish or off-white materials to obtain a white appearance using umbelliferone or methyl umbelliferone |
DE2632810A1 (de) * | 1976-07-21 | 1978-01-26 | Henkel Kgaa | Haarfaerbemittel |
WO1985003864A1 (fr) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Traitement des oedemes a forte teneur en proteines par application directe de benzo-pyrones |
WO1985003865A1 (fr) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Traitement des oedemes a forte teneur en proteines chez les animaux |
DE3938902C1 (fr) * | 1989-11-24 | 1991-05-08 | Schaper & Bruemmer Gmbh & Co, 3320 Salzgitter, De | |
FR2668932A1 (fr) * | 1990-11-14 | 1992-05-15 | Joseph Henri | Preparation d'un gel contenant un extrait de justicia pectoralis jacq. (acanthacees) indique dans le traitement des pathologies lympho-veineuses. |
WO1993016064A1 (fr) * | 1992-02-13 | 1993-08-19 | BIOSIGNAL, Kutató-Fejleszto^' Kft. | Derives de coumarine et leurs analogues inhibant la proliferation cellulaire et la croissance tumorale, compositions pharmaceutiques les contenant, et leur procede de preparation |
EP0665002A1 (fr) * | 1993-12-30 | 1995-08-02 | L'oreal | Composition protectrice, nutritive et/ou raffermissante pour le traitement simultané des couches superficielles et profonde de la peau, son utilisation |
WO1996029050A1 (fr) * | 1995-03-23 | 1996-09-26 | Pierre Fabre Dermo-Cosmetique | Composition dermatologique et/ou cosmetique depigmentante |
WO1998048768A1 (fr) * | 1997-05-01 | 1998-11-05 | Medlogic Global Corporation | Compositions utilisables en cosmetologie |
WO1999047118A1 (fr) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions pour modifier l'aspect exterieur de la peau |
Non-Patent Citations (6)
Title |
---|
BROWN, STEWART A.: "Lactone ring formation of coumarin" Z. NATURFORSCH. (1960), 15B, 768-9, XP001050392 * |
CHEN YUH-FUNG ET AL: "Anti-inflammatory and analgesic activities from roots of Angelica pubescens." PLANTA MEDICA, vol. 61, no. 1, 1995, pages 2-8, XP001050391 ISSN: 0032-0943 * |
DATABASE CA [en ligne] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KOLINEK, JIRI ET AL: "Aqueous extract of Matricaria chamomilla" retrieved from STN Database accession no. 106:219583 XP002184829 & CS 231 474 B (CZECH.) 19 novembre 1984 (1984-11-19) * |
DATABASE WPI Week 199338, 7 septembre 1992 (1992-09-07) Derwent Publications Ltd., London, GB; AN 1993-300929 XP002217449 BOYARSKII V.M. ET AL.: "Balsam" & SU 1 759 870 A (PROIZV PITOMNIKOVODCHESKOE OB), 7 septembre 1992 (1992-09-07) * |
DATABASE WPI Week 199516, 30 août 1994 (1994-08-30) Derwent Publications Ltd., London, GB; AN 1995-121765 XP002217450 BURACHEVSKII ET AL.: "composition of ingredients for liqueur" & RU 2 018 523 A (ARENDNOE PREDPR FIRMA VAGRON (RU)), 30 août 1994 (1994-08-30) * |
WIERZCHOWSKA-RENKE K ET AL: "ÄStudies of the Hierocloe herb. Evaluation of commercial Herba Hierochloe raw material collected at the Zulawy plantationÜ. Badanie ziela turowki (zubrowki) herba hierochloe. 3. Ocena handlowego surowca Herba Hierochloe z plantacji na Zulawach." ACTA POLONIAE PHARMACEUTICA, (1974) 31 (2) 233-9. , XP008007993 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002241071A1 (en) | 2002-10-03 |
WO2002074231A3 (fr) | 2003-02-13 |
FR2822379A1 (fr) | 2002-09-27 |
FR2822379B1 (fr) | 2007-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0585325B1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de cyperus et son procede de fabrication | |
WO1999018927A1 (fr) | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.) | |
EP3054963B1 (fr) | Utilisation cosmétique et/ou dermatologique d'un extrait de feuilles d'hamamelis virginiana | |
FR2684300A1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication. | |
WO2007144521A2 (fr) | Composition cosmetique a usage topique comprenant du wasabi | |
CA2407294A1 (fr) | Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations | |
EP1429720A2 (fr) | Composition cosmetique pour le soin de la peau et des cheveux de l'homme | |
EP2114387B1 (fr) | Utilisation de compositions comprenant au moins une lignane et/ou neolignane pour moduler le taux de testosterone | |
EP1375509A1 (fr) | Utilisation d'une sapogénine, ou d'un extrait naturel en contenant, pour le traitement des peaux sèches oligoséborrhéiques | |
EP0602029B1 (fr) | Composition cosmetique ou pharmaceutique contenant un extrait de coleus esquirolii, de coleus scutellarioides ou de coleus xanthanthus | |
EP0595949B1 (fr) | Compositions pour la pigmentation de la peau ou des cheveux contenant un extrait de marrubium vulgare | |
WO2002047653A2 (fr) | Compositions cosmetiques ou dermopharmaceutiques renfermant des extraits vegetaux de belle de nuit (mirabilis jalapa) | |
WO2002074231A2 (fr) | Compositions cosmetiques et dermopharmaceutiques contenant des extraits titres de hierochloe odorata | |
WO2000028959A1 (fr) | COMPOSITIONS COSMETIQUES OU DERMOPHARMACEUTIQUES CONTENANT UN EXTRAIT DE LARREA DIVARICATA OU DE $i(LARREA TRIDENTATA) | |
FR2854075A1 (fr) | Extraction selective de la figue pour la production d'un ingredient cosmetique et dermopharmaceutique hydratant et rafraichissant | |
WO2000059465A1 (fr) | Compositions cosmetiques ou dermopharmaceutiques renfermant des extraits vegetaux de pinus lambertania contre la secheresse cutanee de toute origine | |
EP2699227A2 (fr) | Complexe d'extraits végétaux pour la protection de la peau. | |
FR2960436A1 (fr) | Composition cosmetique - dermatologique comprenant au moins une huile essentielle et leur utilisation | |
FR3110421A1 (fr) | Extrait de Narcissus poeticus pour son utilisation cosmétique | |
EP1620185A2 (fr) | Composition cosmetique ou pharmaceutique comprenant des acides amides, utilisation, et procedes de traitement dermatologique | |
FR3110416A1 (fr) | Absolue d’ylang-ylang pour son utilisation en tant qu’actif cosmétique | |
FR2974511A1 (fr) | Composition cosmetique comprenant une huile essentielle de lavande et leur utilisation | |
FR3098119A1 (fr) | Procede d’obtention d’une infusion thermale botanique | |
FR2876032A1 (fr) | Utilisation d'extraits de fougeres dans des preparations cosmetiques ou dermatologiques | |
FR2905596A1 (fr) | Association de chelatants naturels comme composition et procede de conservation utilises pour la protection de preparations cosmetiques, pharmaceutiques ou dermatologiques a usage topique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |